Document is current
Any future updates will be listed below
-
Authors
Liu, Dan
Zhou, Jun
Wang, Yongsheng
Li, Mingjun
Jiang, Haiping
Liu, Yunpeng
Yin, Xianli
Ge, Minghua
Xiang, Xiaojun
Ying, Jieer
Huang, Jian
Zhang, Yan-qiao
Cheng, Ying
Huang, Zhigang
Yuan, Xianglin
Han, Weiqing
Yan, Dong
Wang, Xinshuai
Liu, Pan
Wang, Linna
Zhang, Xiaojing
Luo, Suxia
Liu, Tianshu
Shen, Lin
-
Funding
Funding for this research was provided by:
Jiangsu Hengrui Medicine
- License Information
-
More Information
Article History
Received: 9 June 2022
Accepted: 12 October 2022
First Online: 25 October 2022
Declarations
:
: The study was approved by the Ethics Committee of each study center (2018YW96-ZY04, HX-IRB-AF-12-V4.0, L2020-Y004-002, 2020 (No. 516), 2019YL009-3, 2021[No. 142], 2019YW024-A3, 2020 [No. 010]-1, IRB-[2020]-1033, 2020-YW-019-002, 2020-07, 202006-028-03, TREC2020-15.A1, [2019] (339)-2, 2021[No. 12], 2021-LHYW-001-02, 2019-039 (5), 2021-0016, 2019107-010) and conducted in accordance with the Good Clinical Practice and Declaration of Helsinki. All patients provided written informed consent. All authors had access to the study data and reviewed and approved the final manuscript.
: Not applicable
: PL, LW, and XZ are employees of Jiangsu Hengrui Pharmaceuticals. The other authors declare no competing interests.
